RebeccaKruse-JarresMD

PubMed

• Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort.
  Jacqueline N Poston, Cassandra Bryan, Annette von Drygalski, Kadhim Al Banaa, Jenny Y Zhou
  Blood Advances. 2024-11-26
• 8 citations
  Quantitative measurements of haemophilic joint tissues by point-of-care musculoskeletal ultrasound: Associations with clinical and functional joint outcome parameters.
  Akram Mesleh Shayeb, Richard F. W. Barnes, Cris Hanacek, Peter Aguero, Bruno Steiner
  Haemophilia. 2021-06-25
• 444 citations
  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
  Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli
  The New England Journal of Medicine. 2018-08-29

Abstracts/Posters

• Patterns and Predictors of Emicizumab Adherence in People with Hemophilia
  Rebecca Kruse-Jarres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Quantitative Measurements of Hemophilic Joint Tissues By Point-of-Care Musculoskeletal Ultrasound Are Associated with Clinical and Functional Joint Outcome Parameters
  Rebecca Kruse-Jarres, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Urinary Cross-Linked Carboxyterminal Telopeptide Decreases with Resolution of Painful Vaso-Occlusive Crises in Adults with Sickle Cell Disease - Results from the Sickl... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• What to Do When a Pre-Op Patient Has Abnormal Prothrombin Time (PT) or Partial Thromboplastin Time (PTT) 
  60th American Society of Hematology Annual Meeting - 11/30/2018